Pieris Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$22.22M
-11.09
$53K
Pieris Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2014-12-18. Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Pieris Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2014-12-18. Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Recently from Cashu
Greywolf Therapeutics Appoints New CFO with Experience at Pieris Pharmaceuticals
Greywolf Therapeutics Bolsters Leadership with New CFO Appointment Greywolf Therapeutics, a clinical-stage biotech firm based in Oxford, has announced the appointment of Darlene Deptula-Hicks as its n…
Darlene Deptula-Hicks Joins Greywolf: Former CFO of Pieris Pharmaceuticals Enhances Biotech Strategy
Darlene Deptula-Hicks Joins Greywolf Therapeutics as CFO: A Strategic Move for Biotech Advancement Greywolf Therapeutics, a clinical-stage biotech firm based in Oxford, England, announces the appointm…